advertisement
Grus FH 8
Showing records 1 to 8 | Display all abstracts from Grus FH106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Tonner H
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Fomo KN; Schmelter C
Frontiers in medicine 2022; 9: 993351
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Hunn S; Auler N
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Atta J; Beutgen VM
Frontiers in medicine 2022; 9: 993351
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Schmelter C
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Beutgen VM; Schwarz R
Frontiers in medicine 2022; 9: 993351
106321 Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
Pfeiffer N; Grus FH
International journal of molecular sciences 2022; 23:
106224 Synthetic antibody-derived immunopeptide provides neuroprotection in glaucoma through molecular interaction with retinal protein histone H3.1
Perumal N; Govind G; Speck T; Pfeiffer N; Grus FH
Frontiers in medicine 2022; 9: 993351
